CN Patent

CN115554237B — 一种卢美哌隆原位凝胶长效注射剂及其制备方法和用途

Assigned to Shandong Hi Qual Pharmatech Co ltd · Expires 2023-09-12 · 3y expired

What this patent protects

本发明属于药物制剂技术领域，其公开了一种卢美哌隆原位凝胶长效注射剂及其制备方法和用途，所述卢美哌隆原位凝胶长效注射剂，包括卢美哌隆或其医学上可接受的盐、凝胶基质、溶剂和多糖速率调节剂。本发明既可以减少给药次数，显著提高患者的顺应性，同时，还可以有效降低药物活性成分的突释效应，提高了药物的安全有效性。

USPTO Abstract

本发明属于药物制剂技术领域，其公开了一种卢美哌隆原位凝胶长效注射剂及其制备方法和用途，所述卢美哌隆原位凝胶长效注射剂，包括卢美哌隆或其医学上可接受的盐、凝胶基质、溶剂和多糖速率调节剂。本发明既可以减少给药次数，显著提高患者的顺应性，同时，还可以有效降低药物活性成分的突释效应，提高了药物的安全有效性。

Drugs covered by this patent

Patent Metadata

Patent number
CN115554237B
Jurisdiction
CN
Classification
—
Expires
2023-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Shandong Hi Qual Pharmatech Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.